Vir Biotechnology, Inc.
1800 Owens Street
Suite 900
San Francisco, CA 94158
United States
415 906 4324
https://www.vir.bio
版塊: Healthcare
行業: Biotechnology
全職員工: 587
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Marianne De Backer M.B.A., M.Sc., Ph.D. | CEO & Director | 4.47M | 無 | 1969 |
| Dr. Ann M. Hanly Ph.D. | Executive VP & Chief Technology Officer | 896.07k | 無 | 1970 |
| Dr. Jeff Calcagno M.D. | Executive VP & Chief Business Officer | 860.49k | 無 | 1961 |
| Dr. Klaus Frueh Ph.D. | Co-Founder & Scientific Advisor | 177.66k | 無 | 1960 |
| Dr. Lawrence Corey M.D. | Co-Founder & Scientific Advisor | 無 | 無 | 1947 |
| Dr. Louis J. Picker M.D. | Co-Founder & Scientific Advisor | 無 | 無 | 無 |
| Dr. Jennifer Eileen Towne Ph.D. | Executive VP & Chief Scientific Officer | 無 | 無 | 無 |
| Ms. Heather Rowe Armstrong | Vice President of Investor Relations | 無 | 無 | 無 |
| Ms. Vanina De Verneuil J.D. | Executive VP, General Counsel & Corporate Secretary | 無 | 無 | 無 |
| Cara Miller | Vice President of Corporate Communications | 無 | 無 | 無 |
描述
Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.
公司管治
截至 2024年6月1日 止，Vir Biotechnology, Inc. 的 ISS 管治質素評分為 10。 Pillar 分數正在審核中：4；董事會：7；股東權利：8；現金賠償：10。
